Last updated on March 2007

Bortezomib and Low Dose Cytarabine in the Treatment of High-Risk Myelodysplastic Syndromes


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Myelodysplastic Syndromes
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other:
    MDS with IPSS scores Int-2 or High
    Life expectancy greater than 6 months
    No other available treatment options

You may not be eligible for this study if the following are true:

  • MDS with IPSS scores Low or Int-1
    > 30% bone marrow blasts
    clinical neuropathy of greater than grade 2
    ECOG Score 3 or 4
    Creatinine clearance of < 30 ml/min
    LMMC
    Pregnant patients or lactating mothers
    Patients having received intensive chemotherapy in the 3 months prior to inclusion
    Patients with uncontrolled pulmonary, cardiac, neurological, gastro-intestinal or
    genito-urinary disorders

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.